Alzheimer's
**Drug Discovery**
Foundation

# 2025 PORTFOLIO SNAPSHOT

*Milestones in Motion*

# *Dear Friends,*

This past year has marked extraordinary progress in Alzheimer's research – much of it powered by the ADDF's bold vision. Every step forward carries special meaning following the loss of our beloved Co-Founder Leonard A. Lauder, whose passion continues to inspire us. Through the innovative projects outlined in this report, we are driving the field toward combination therapies and precision medicine – an approach that will revolutionize treatment for millions around the world.

The FDA's recent approval of the Lumipulse blood test was a key milestone, supported in part by our Diagnostics Accelerator (DxA). Like cholesterol tests revolutionized heart disease care, blood tests will transform Alzheimer's diagnosis, making it more routine and accessible. And we're not stopping there – the DxA is advancing an array of promising digital biomarkers and other cutting-edge diagnostics to enable earlier detection and treatment.

On the drug development front, we are advancing novel therapies informed by the biology of aging, which will be combined with existing amyloid treatments for greater impact – an approach the ADDF has championed from day one. Thanks to our leadership, these innovative drugs now make up more than 70% of the pipeline.

We are also leading the precision prevention movement – combining lifestyle and therapeutic strategies tailored to individual biology. By partnering with global leaders in prevention, we are building the tools needed to personalize care and protect brain health earlier and more effectively.

Thanks to your partnership, we are accelerating the most promising science at a time when momentum truly matters. The future of Alzheimer's care is being built today, catalyzed by your generous support.

With gratitude,

Howard

**HOWARD FILLIT, M.D.**
Co-Founder and Chief Science Officer

Mark

**MARK ROITHMAYR**
Chief Executive Officer

# OUR PORTFOLIO BY THE NUMBERS

## Active Projects

**126**
Projects

**Projects Funded in 21 Countries**

**Nearly $200M Currently Invested**

**73**
Academia Investments

**53**
Biotech investments

**5**
Innovative Combination Therapy Trials

*As of July 7, 2025



# THE ADDF VENTURE PHILANTHROPY MODEL

**1 Search**
Proactive assessments of the field and several funding rounds

**2 Due Diligence**
*Internal:* 11 expert neuroscientists

*External:* 160+ reviewers from academia, biotech, pharma, and VC

**3 Monitoring**
Track success, foster partnerships, and diligent follow-up

**4 Reinvest**
Funnel returns into further investments to keep scientific innovation moving forward

*Applying the rigor of venture capital to attract and support the most promising science*

## Returns are Reinvested

Funding is structured to enable returns on investment, which are reinvested into further scientific exploration.

More than **$30M** all reinvested back into the pipeline.

# PROJECT SPOTLIGHTS

## Andrew Satlin, MD

**PROGRAM**
*Therapeutics, Clinical Phase 2*

Transposon Therapeutics is testing a novel drug, TPN-101, to treat Alzheimer's disease. The drug targets LINE-1 DNA elements – segments of "junk" DNA that, when activated by the tau proteins present in Alzheimer's, produce a response that mimics a viral immune trigger. This activation leads to inflammation, DNA damage, and neuronal cell death. TPN-101 aims to halt this inflammatory cascade and preserve brain cells, potentially slowing disease progression. The ADDF is supporting Transposon's phase 2 clinical trial.

## Bradford Navia, MD, PhD

**PROGRAM**
*Therapeutics, Clinical Phase 1*

Therini Bio's drug candidate, THN391, fights inflammation – a key target as we develop the next generation of treatments informed by the biology of aging. In April 2025, Therini announced positive results from the drug's phase 1a trial, showing THN391 to be well tolerated in healthy subjects. It has been gratifying to see the ADDF's support of this program attract other key players in the Alzheimer's field, including the Foundation For a Better World, Eli Lilly, and Apollo Health Ventures. Therini plans to commence a phase 1b trial in the coming months.

## Manu Vandijck

**PROGRAM**
*Diagnostics, Blood*

In a critical milestone for the fight against Alzheimer's, Fujirebio's Lumipulse pTau217/β-Amyloid Ratio recently became the first Alzheimer's blood test cleared by the FDA. Blood tests like this can be deployed in a wide range of clinical settings, including primary care, and are key to detecting the disease earlier, speeding up clinical trials, and paving the way for more targeted treatments. The ADDF is supporting the development of Fujirebio's next generation pTau217 blood test.

## Consortium

**PROGRAM**
*Diagnostics, Digital*

The ADDF's Diagnostics Accelerator established SpeechDx to create the largest longitudinal dataset of speech in Alzheimer's and pre-Alzheimer's patients, enrolling up to 2,000 participants who will be monitored for 3 years. Speech is increasingly recognized as a potential predictor of cognitive decline and is easily measured with common smart devices. This year, the ADDF announced a new partnership with Siemens Healthineers to license SpeechDx's dataset with the goal of developing speech-based biomarkers that can help predict who is likely to develop Alzheimer's and when the disease may occur.

# THE ADDF PORTFOLIO

## CLINICAL TRIALS

### GENETICS AND EPIGENETICS

**Weill Medical College of Cornell University** 🕮
**Lexeo Therapeutics Inc.**
Ronald Crystal
*Clinical Phase 1*

Ronald Crystal *c*
*Clinical Phase 1*

### INFLAMMATION

**Coya Therapeutics**
Fred Grossman
*Clinical Phase 2*

**Dignity Health St Joseph's Hospital and Medical Center** 🕮
Marwan Sabbagh
*Clinical Phase 2*

**NeuroTherapia, Inc.**
Tony Giordano
*Clinical Phase 2*

**Therini Bio**
Bradford Navia
*Clinical Phase 1*

**Transposon Therapeutics**
Andrew Satlin
*Clinical Phase 2*

**University of Alabama at Birmingham** 🕮
Erik Roberson
*Target Discovery*

**University of California at Davis** 🕮
John Olichney
*Drug Manufacture*

### MITOCHONDRIA AND METABOLIC FUNCTION

**Amsterdam UMC Research BV** 🕮
E.G.B. Vijverberg
*Clinical Phase 1*

**Metro International Biotech**
David Livingston
*Clinical Phase 2*

**Metro International Biotech**
David Livingston
*Clinical Phase 2*

### NEUROPROTECTION

**Cognito Therapeutics**
Ralph Kern
*Clinical Phase 3*

**Imperial College London** 🕮
Paul Edison
*Clinical Phase 2*

**Massachusetts General Hospital** 🕮
Emiliano Santarnecchi *a*
*Clinical Phase 2*

**MTI BioTech Inc.**
John Rathmacher
*Clinical Phase 2*

**Treeway B.V.**
Ronald van der Geest *c*
*Clinical Phase 2*

**PharmatrophiX**
Anne Longo
*Drug Manufacture*

### SENESCENCE

**Wake Forest University** 🕮
Miranda Orr
*Clinical Phase 2*

### SYNAPTIC ACTIVITY & NEUROTRANSMITTERS

**Brown University** 🕮
Edward Huey *a*
*Clinical Phase 2*

**Curasen Therapeutics Inc.**
Gabriel Vargas
*Clinical Phase 1*

**McGill University** 🕮
Simon Ducharme *a*
*Clinical Phase 2*

**NeuroScios GmbH**
Giacomo Koch
*Clinical Phase 3*

**NSC-Therapeutics GmbH**
Manfred Windisch
*Clinical Phase 2*

**Sunnybrook Research Institute** 🕮
Krista Lanctôt
*Clinical Phase 2*

**University of Exeter** 🕮
Clive Ballard
*Clinical Phase 2*

### MULTI-CATEGORY

**FINGERS Brain Health Institute** 🕮
Miia Kivipelto
*Clinical Trial Design and Implementation Resources*

Principal Investigator
Biotechnology Organization
Academic/Nonprofit Organization

*a* In Partnership with the Association for Frontotemporal Degeneration
*b* Collaboration with the Harrington Discovery Institute
*c* Follow-on Funding

# PRE-CLINICAL PROGRAMS

## GENETICS AND EPIGENETICS

**University of Dundee**
Rosemary Jackson *b*

## INFLAMMATION

**Astrocyte Pharmaceuticals Inc.**
James Lechleiter

**Case Western Reserve University**
Paul Tesar *b*

**Indiana University**
Timothy Richardson *b*

**Modulo Bio, Inc.**
Ryan Lim

**St. Vincent's Institute of Medical Research**
Michael Parker

**UHN-Krembil**
Donald Weaver *b*

**UniQuest**
Andrew Harvey

## MISFOLDED PROTEINS

**Aquinnah Pharmaceuticals**
Glenn Larsen

**Johns Hopkins University**
Jeffrey Rothstein *a*

**Polku Therapeutics**
Timo Myöhänen *a*

**University of California, Santa Barbara**
Kenneth Kosik *a*

## MITOCHONDRIA AND METABOLIC FUNCTION

**GliaPharm SA**
Pierre Magistretti

## NEUROPROTECTION

**Pangea Botanica Ltd**
Alleyn Plowright

## SYNAPTIC ACTIVITY AND NEUROTRANSMITTERS

**Cleveland Clinic Foundation**
Dianne Perez

**University of Minnesota**
Karen Ashe

## OTHER

**Emory University**
Thomas Kukar *a*

# DIAGNOSTICS ACCELERATOR

## DIGITAL

**Boston University**
Rhoda Au

**C. Light Technologies, Inc.**
Christy Sheehy

**Cogstate Ltd**
Pam Ventola

**ETH Zurich**
Rafael Polania

**ki elements**
Nicklas Linz

**MoCA Cognition**
Ziad Nasreddine

**neotiv GmbH**
David Berron

**Neurotrack Technologies, Inc**
Russell Banks *d*

**SpeechDX**
Partnership

**The Chinese University of Hong Kong**
Guoliang Xing

**UsAgainstAlzheimer's**
Ben Tiede

**ViewMind**
Yaakov Stern

## GENETICS AND EPIGENETICS

**ADmit Therapeutics S.L.**
Marta Barrachina *c*

**Amoneta Diagnostics**
Hueseyin Firat *c*

**Hummingbird Diagnostics GmbH**
Bruno Steinkraus

**NeuroAge Therapeutics**
Christin Glorioso

## INFLAMMATION

**Bluefield Project to Cure FTD**
Laura Mitic *a*

**Foundation for the National Institutes of Health, Inc.**
Rohini Khilian *a*

**Monash University**
Matthew Pase *a*

## MISFOLDED PROTEINS

**Banner Health**
Nicholas Ashton

**C2N Diagnostics**
Joel Braunstein

**Centre for Eye Research Australia**
Peter van Wijngaarden

Principal Investigator
Biotechnology Organization
Academic/Nonprofit Organization

*a* In Partnership with the Association for Frontotemporal Degeneration
*b* Collaboration with the Harrington Discovery Institute
*c* Follow-on Funding

**Circular Genomics Inc**
Nikolaos Mellios

**Davos Alzheimers Collaborative**
Phyllis Ferrell

**Foundation for the National Institutes of Health, Inc.**
Rohini Khilian

**Fujirebio Europe NV**
Manu Vandijck *c*

**NeuroDex**
Erez Eitan

**Optina Diagnostics**
Jean-Philippe Sylvestre *c*

**Sunbird Bio**
Mario Morken

**University of Gothenburg**
Henrik Zetterberg

**University of Utah**
Qinwen Mao *a*

**University of Washington**
Cecilia Lee

## MITOCHONDRIA AND METABOLIC FUNCTION

**Esya Inc**
Souvik Modi

**University of Washington**
Heather Wilkins

## VASCULAR DISEASE

**GLX Analytix ApS**
Brian Della Valle

## OTHER

**Alamar Biosciences**
Xiao-Jun Ma

**Quanterix Corporation**
David Wilson

**Startup Health, LLC**
Elizabeth Dale

**Stichting Amsterdam UMC**
Betty Tijms

**University of Gothenburg**
Henrik Zetterberg



# OTHER BIOMARKER PROGRAMS

## INFLAMMATION

**Foundation for the National Institutes of Health, Inc.**
Rohini Khilian

**Life Molecular Imaging, Ltd**
Andrew Stephens

**Mayo Clinic Rochester**
Val Lowe

**MindImmune Therapeutics, Inc.**
Frank Menniti

**Virginia Commonwealth University**
Shijun Zhang

## MISFOLDED PROTEINS

**APRINOIA Therapeutics Inc**
Lili Zhang

**Johns Hopkins University**
Philip Wong *a*

**The University of Edinburgh**
Neil McKenzie

**University College London**
Simon Mead

## SYNAPTIC ACTIVITY & NEUROTRANSMITTERS

**BrainScope Company, Inc**
Leslie Prichep

## VASCULAR DISEASE

**IMAGINOSTICS INC**
Codi Gharagouzloo

**TUFTS Medical Center**
David Kent

## MULTI-CATEGORY

**University of Nevada Las Vegas**
Jeffrey Cummings

Principal Investigator
Biotechnology Organization
Academic/Nonprofit Organization

*a* In Partnership with the Association for Frontotemporal Degeneration
*b* Collaboration with the Harrington Discovery Institute
*c* Follow-on Funding

### GENETICS AND EPIGENETICS

**University of Southern California**
Hussein Yassine
*Clinical Phase 2*

### MISFOLDED PROTEINS

**University of Arizona**
Roberta Brinton
*Clinical Phase 2*

### MITOCHONDRIA AND METABOLIC FUNCTION

**Sunnybrook Research Institute**
Walter Swardfager
*Epidemiology*

### OTHER

**Imperial College London**
Miia Kivipelto
*Clinical Phase 2*

**Preventive Medicine Research Institute**
Dean Ornish
*Clinical Phase 2*

**Monash University**
Joanne Ryan
*Clinical Phase 4*

**FINGERS Brain Health Institute**
Miia Kivipelto

Principal Investigator
Biotechnology Organization
Academic/Nonprofit Organization

*a* In Partnership with the Association for Frontotemporal Degeneration
*b* Collaboration with the Harrington Discovery Institute
*c* Follow-on Funding



# THANK YOU TO ALL OF OUR SUPPORTERS

Thank you to our dedicated community of supporters and friends. Your commitment makes the critical work highlighted in this report possible. Together, we will bring effective treatments to the millions of Alzheimer's patients and families around the world. For more information on our work or to make a donation, please visit

**WWW.ALZDISCOVERY.ORG.**

The mission of the Alzheimer's Drug Discovery Foundation is to rapidly accelerate the development of drugs to prevent, treat and cure Alzheimer's disease.

ALZDISCOVERY.ORG

♥ Give online

Alzheimer's
**Drug Discovery**
Foundation